

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/201051 A1

(51) International Patent Classification:
C07C 235/14 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:
PCT/GB2024/050853

(22) International Filing Date:
28 March 2024 (28.03.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
23165829.5 31 March 2023 (31.03.2023) EP

(71) Applicant: **NXERA PHARMA UK LIMITED** [GB/GB];
Granta Park, Great Abington, Cambridge Cambridgeshire
CB21 6DG (GB).

(72) Inventors: **MANAGE, Ajith**; c/o HEPTARES THERA-
PEUTICS LIMITED, Granta Park, Great Abington, Cam-
bridge Cambridgeshire CB21 6DG (GB). **MOHR, Aman-**
dine; c/o HEPTARES THERAPEUTICS LIMITED, Gran-
ta Park, Great Abington, Cambridge Cambridgeshire CB21
6DG (GB).

(74) Agent: **GILL JENNINGS & EVERY LLP**; The
Broadgate Tower, 20 Primrose Street, London EC2A 2ES
(GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: CRYSTALLINE FORM OF AN EP4 ANTAGONIST




FIG. 1

(57) Abstract: This invention relates to a crystalline form of the compound of Formula (1) (1) (1). The invention also relates to compositions and pharmaceutical compositions comprising the crystalline form, to medical uses of the crystalline form, and methods of preparing the crystalline form.

[Continued on next page]

WO 2024/201051 A1

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*